Overview
Morgan Stanley adjusted its stance within the contract research organization (CRO) sector, raising Charles River Laboratories and lowering its rating on IQVIA Holdings. The bank said improving biopharma funding and strategic portfolio changes have improved Charles River's risk-reward profile, while questions about the pace and scope of artificial intelligence adoption and possible pharma insourcing introduce valuation risk for IQVIA.
Charles River: signs of a turnaround
The firm highlighted early evidence that demand for preclinical research is picking up as biopharma funding recovers, which increases the chance of a recovery in Charles River's Discovery and Safety Assessment segment. Morgan Stanley also pointed to recent acquisitions and divestitures that are expected to concentrate Charles River's operations on regulated safety assessment, research models and biologics testing.
With that view, Morgan Stanley upgraded Charles River to an Overweight rating and attached a $220 price target. The bank noted that the valuation implies roughly 14 times Charles River's 2026 EBITDA estimate. Morgan Stanley expects Charles River to benefit from higher outsourcing penetration, geopolitical shifts and its scale in preclinical research, and it projects double-digit earnings growth for the company through 2028.
IQVIA: AI, insourcing and leverage create questions
At the same time, Morgan Stanley downgraded IQVIA to Equal-weight and lowered its price target to $200 from $225. The bank said investor debate has increased around whether pharmaceutical companies could leverage AI tools to internalize functions that have traditionally been outsourced to CROs, such as data management, statistical analysis and medical writing.
Morgan Stanley estimated that roughly 30% of typical clinical trial costs relate to functions commonly outsourced to CROs and noted that large drugmakers are investing in AI-enabled infrastructure that could enable some of that work to be performed internally over time. While the bank does not anticipate immediate downside to IQVIA's earnings forecasts, it flagged the uncertainty about how AI and pharma insourcing will evolve as a potential limitation on valuation expansion.
In addition to the AI-related uncertainty, Morgan Stanley highlighted IQVIA's leverage profile. The bank said higher interest costs and upcoming debt maturities could reduce IQVIA's flexibility for future share repurchases, a mechanism that has materially supported earnings-per-share growth in recent years.
Firm positioning and outlook
Despite the downgrade, Morgan Stanley acknowledged that IQVIA remains well positioned because of its data assets, technology offerings and diversified exposure across clinical research and commercial services. The brokerage emphasized, however, that a clearer demonstration of sustained demand and tangible AI-driven benefits will be necessary before IQVIA can justify a higher valuation multiple in the view of investors.
Implications for markets and sectors
The bank's repositioning reflects shifting expectations for CROs amid a rehabilitation in biotech funding and the uncertain pace of technology-driven change in pharma operations. The assessment touches on the preclinical and clinical research supply chain, the outsourcing dynamics between drugmakers and service providers, and the potential impact of AI investments within pharmaceutical companies.